Financial Performance - In Q3 2025, Linde's sales reached $8,615 million, a 3% increase from the previous year, driven by a 2% rise in pricing and a 1% contribution from acquisitions [109]. - Reported operating profit for Q3 2025 was $2,367 million, representing a 13% year-over-year increase, with an operating margin of 27.5% [110]. - Adjusted operating profit for Q3 2025 was $2,558 million, up 3% from 2024, with an adjusted operating margin of 29.7% [111]. - Reported net income for Linde plc increased by $379 million, or 24%, in Q3 2025 compared to Q3 2024, and by $528 million, or 11%, for the nine months ended September 30, 2025 [130]. - Adjusted diluted earnings per share (EPS) increased by $0.27, or 7%, for Q3 2025, and by $0.72, or 6%, for the nine months ended September 30, 2025, driven by higher net income and lower diluted shares outstanding [133]. - Reported net income for Q3 2025 was $1,929 million, up from $1,550 million in Q3 2024, reflecting a 24% increase [177]. Tax and Earnings - The effective tax rate decreased to 18.0% in Q3 2025 from 24.1% in Q3 2024, contributing to a diluted EPS of $4.09, a 27% increase year-over-year [110]. - The effective tax rate (ETR) for Q3 2025 was 18.0%, down from 24.1% in Q3 2024, primarily due to a tax rate decrease in EMEA, resulting in a benefit of $156 million [125]. Sales and Segments - Total sales for the company increased by 3% to $8,615 million in Q3 2025, and by 2% to $25,222 million for the nine months ended September 30, 2025, compared to the respective 2024 periods [140]. - The Americas segment reported a sales increase of $228 million, or 6%, in Q3 2025, with higher pricing contributing 3% to sales [142]. - EMEA segment sales increased by $67 million, or 3%, in Q3 2025, with currency translation contributing a 5% increase due to the strengthening of the Euro and British pound [147]. - APAC segment sales increased by $25 million, or 1%, in Q3 2025, but decreased by $29 million, or 1%, for the nine months ended September 30, 2025, compared to 2024 [150]. - Engineering segment sales decreased by $92 million, or 15%, in Q3 2025, and by $59 million, or 3%, for the nine months ended September 30, 2025, driven by project timing [153]. - Other segment sales increased by $31 million, or 10%, in Q3 2025, and by $18 million, or 2%, for the nine months ended September 30, 2025, primarily due to higher volumes in Linde Advanced Material Technologies [158]. Expenses and Costs - Cost of sales, excluding depreciation and amortization, was 50.8% of sales in Q3 2025, down from 52.1% in Q3 2024, reflecting higher pricing and productivity gains [115]. - Selling, general and administrative expenses rose by 9% in Q3 2025, accounting for 10.4% of sales, compared to 9.8% in the same quarter of 2024 [116]. - Net pension and OPEB cost benefit was $57 million for Q3 2025, up from $45 million in Q3 2024, primarily due to lower interest costs [124]. Cash Flow and Investments - Cash provided by operations was $7,320 million for the nine months ended September 30, 2025, an increase of $706 million, or 11%, compared to 2024 [163]. - Net cash used for investing activities was $4,260 million for the nine months ended September 30, 2025, an increase of $992 million, or 30%, versus 2024, due to higher capital expenditures and acquisition spend [164]. - Capital expenditures for the nine months ended September 30, 2025, were $3,803 million, $556 million higher than the prior year, primarily for new plant and production equipment [164]. - Cash used for financing activities was $3,536 million for the nine months ended September 30, 2025, compared to $2,749 million for the same period in 2024 [169]. - Cash dividends increased by $117 million to $2,113 million, driven by an 8% increase in quarterly dividends per share from $1.39 to $1.50 [171]. Employee and Operational Metrics - The number of employees decreased by 107 to 65,489 as of September 30, 2025, primarily due to ongoing cost reduction programs [134]. - Other comprehensive loss for Q3 2025 was $165 million, primarily due to currency translation adjustments of $167 million [138]. - Noncontrolling interests income was reported at $43 million for Q3 2025, down from $53 million in Q3 2024, reflecting the impact of a divestiture in the APAC segment [129]. Balance Sheet and Assets - Current assets as of September 30, 2025, were $5,442 million, a decrease from $7,827 million at the end of December 31, 2024 [193]. - Long-term assets increased to $16,355 million as of September 30, 2025, compared to $14,481 million at the end of December 31, 2024 [193]. - Current liabilities rose to $12,190 million as of September 30, 2025, compared to $10,309 million at the end of December 31, 2024 [193]. - Long-term liabilities increased to $70,688 million as of September 30, 2025, from $64,848 million at the end of December 31, 2024 [193].

Financial Performance - In Q3 2025, Stryker Corporation achieved net sales of $6,057 million, representing a 10.3% increase from Q3 2024[90]. - For the first nine months of 2025, sales grew by 11.1% to $17,945 million compared to the same period in 2024[83]. - Net earnings for Q3 2025 were $859 million, with adjusted net earnings of $1,233 million, reflecting an 11.1% increase from 2024[82]. - Consolidated net sales increased by 10.3% in Q3 2025, reaching $6,057 million, with a 9.6% increase in constant currency[93]. - The company reported adjusted net earnings of $4,439 million for the nine months ended 2025, with an adjusted effective tax rate of 14.6%[129]. Operating Income and Margins - The operating income margin for Q3 2025 was reported at 18.7%, while the adjusted operating income margin increased by 90 basis points to 25.6%[82]. - Operating income for Q3 2025 was $1,135 million, with a decrease in operating margin to 18.7% from 19.7% in Q3 2024[103]. - The company reported a 20.4% increase in adjusted operating income compared to the previous year[124]. Segment Performance - In Q3 2025, the MedSurg and Neurotechnology segment reported sales of $3,803 million, a 14.4% increase from Q3 2024[91]. - The Orthopaedics segment achieved sales of $2,254 million, marking a 3.9% increase from the previous year[91]. - Orthopaedics net sales rose by 3.9% in Q3 2025, totaling $2,248 million, with a 11.7% increase in constant currency excluding acquisitions[97]. - MedSurg and Neurotechnology net sales increased by 14.4% in Q3 2025, amounting to $2,254 million, with a 7.6% increase in constant currency excluding acquisitions[95]. Expenses - Research, development, and engineering expenses for Q3 2025 were $410 million, an increase of 8.8% from Q3 2024[90]. - Selling, general, and administrative expenses rose by 8.0% in Q3 2025, amounting to $2,046 million, with a decrease in percentage of net sales to 33.8%[108]. - Research, development, and engineering expenses increased by 8.8% in Q3 2025, totaling $406 million, remaining flat as a percentage of net sales[107]. Tax and Other Income - The effective tax rate for Q3 2025 was 16.5%, down from 20.0% in Q3 2024, due to discrete tax items and benefits from European operations[114]. - Other income (expense), net was ($106) million in Q3 2025, primarily due to higher interest expenses compared to ($42) million in Q3 2024[113]. - Adjustments related to tax matters resulted in a net benefit of $71 million for the nine months ended 2025, compared to $135 million in 2024[132]. Cash Flow and Liquidity - The company experienced an increase in cash provided by operating activities to $2,901 million in 2025 from $2,311 million in 2024, primarily due to the timing of payments and collections[134]. - Cash used in investing activities rose significantly to $4,561 million in 2025 from $2,697 million in 2024, driven by the acquisition of Inari and capital expenditures[135]. - Cash provided by financing activities was $1,206 million in 2025, slightly down from $1,269 million in 2024, with proceeds primarily from the issuance of senior unsecured notes[136]. - As of September 30, 2025, cash, cash equivalents, short-term investments, and marketable securities totaled $3,343 million, down from $4,493 million at the end of 2024[137]. - Current assets exceeded current liabilities by $6,297 million as of September 30, 2025, compared to $7,231 million at the end of 2024, indicating a decrease in liquidity[137]. Acquisitions - The company completed the acquisition of Inari in Q1 2025 for a total consideration of $4,810 million[86]. - Acquisition and integration-related costs included $61 million for inventory stepped-up to fair value and $39 million for other integration-related activities[124]. Legal and Regulatory Matters - The company is involved in various ongoing legal proceedings related to product, labor, and intellectual property matters[142]. - The company anticipates that new tax laws could increase tax expenses in future periods, with a global corporate minimum tax rate of 15% being implemented[117]. Forward-Looking Statements - The report contains forward-looking statements based on current projections about operations and financial conditions, which are subject to risks and uncertainties[143]. - The company has expressed no intention to update or revise any forward-looking statements unless necessary[143]. - The company emphasizes that actual results could differ materially from forward-looking statements due to various factors[143].

Sales Performance - Approximately two-thirds of Colgate-Palmolive's net sales are generated from markets outside the U.S., with about 45% coming from emerging markets[105]. - Worldwide net sales for Colgate-Palmolive Company were $5,131 million in Q3 2025, up 2.0% from Q3 2024, driven by net selling price increases of 2.3% and positive foreign exchange of 1.2%[129]. - Organic sales increased by 0.4% in Q3 2025, excluding the impact of foreign exchange, acquisitions, and divestments[129]. - In the Oral, Personal and Home Care segment, net sales were $3,989 million, up 2.1% from Q3 2024, with organic sales increasing by 0.9%[130]. - In the Hill's Pet Nutrition segment, net sales were $1,142 million, up 1.4% from Q3 2024, but organic sales decreased by 1.3%[132]. - North America net sales decreased 0.4% to $999 million, with operating profit down 8% to $190 million, representing 19.0% of net sales[151]. - Latin America net sales increased 2.0% to $1,178 million, while operating profit decreased 8% to $337 million, accounting for 28.6% of net sales[154]. - Europe net sales rose 7.6% to $801 million, with operating profit increasing 16% to $209 million, representing 26.1% of net sales[158]. - Asia Pacific net sales fell 1.5% to $714 million, and operating profit decreased 6% to $188 million, accounting for 26.2% of net sales[161]. - Africa/Eurasia net sales increased 6.8% to $297 million, with operating profit rising 5% to $68 million, representing 23.0% of net sales[165]. - Pet Nutrition net sales increased by 2.2% in the first nine months of 2025, with an impact from the acquisition of the Prime100 pet food business contributing 0.9% to reported volume[178]. - Total company net sales growth for the three months ended September 30, 2025, was 2.0%, with organic sales growth at 0.4%[221]. - In the nine months ended September 30, 2025, total company net sales growth was flat at 0.0%, while organic sales growth was 1.2%[223]. Financial Performance - Gross profit decreased to $3,049 million in Q3 2025 from $3,074 million in Q3 2024, with a gross profit margin of 59.4%, down from 61.1%[133][134]. - Operating profit decreased by 1% to $1,059 million in Q3 2025, with an operating profit margin of 20.6%, down from 21.2% in Q3 2024[141][142]. - Net income attributable to Colgate-Palmolive Company was $735 million in Q3 2025, a slight decrease from $737 million in Q3 2024, while diluted earnings per share increased to $0.91[147][148]. - Operating profit increased to $3,214 million in the first nine months of 2025 from $3,205 million in 2024, marking a 0.3% increase[188]. - Gross profit decreased to $9,105 million in the first nine months of 2025 from $9,179 million in 2024, primarily due to a lower gross profit margin of 60.1% compared to 60.6% in the prior year[179][180]. - The effective income tax rate for the first nine months of 2025 was 23.2%, a slight decrease from 23.4% in the same period of 2024[197]. - Interest expense decreased to $203 million in the first nine months of 2025 from $226 million in 2024, while interest income increased to $56 million from $51 million[194][195]. - The effective income tax rate for the three months ended September 30, 2025, was 22.8%, compared to 21.3% for the same period in 2024[204]. - In the first nine months of 2025, net income attributable to Colgate-Palmolive Company increased to $2,169 million from $2,150 million in the comparable 2024 period, with diluted earnings per share rising to $2.67 from $2.61[207]. - Excluding certain charges, net income attributable to Colgate-Palmolive Company in the first nine months of 2025 increased to $2,228 million from $2,217 million in the first nine months of 2024, with diluted earnings per share increasing 2% to $2.74 from $2.69[208]. Costs and Expenses - The company expects incremental gross costs of approximately $75 million in 2025 due to tariffs imposed by the United States and other countries[121]. - Colgate-Palmolive continues to experience higher raw and packaging material costs, which may adversely affect future results[124]. - The decrease in gross profit margins across segments was primarily due to significantly higher raw and packaging material costs, partially offset by cost savings initiatives[153][157][160][164][167]. - Selling, general and administrative expenses decreased to $1,971 million in Q3 2025 from $1,979 million in Q3 2024, with a percentage of net sales decreasing by 90 basis points to 38.4%[136][137]. - Selling, general and administrative expenses remained flat at $5,833 million for both periods, but decreased to $5,817 million when excluding specific charges[182][184]. - Non-service related postretirement costs increased to $116 million in the first nine months of 2025 from $67 million in 2024, primarily due to charges related to the ERISA litigation matter[192]. Strategic Initiatives - The Strategic Growth and Productivity Program is estimated to result in cumulative pre-tax charges totaling between $200 million and $300 million, with most charges expected to be incurred by December 31, 2028[116]. - The company aims to achieve consistent organic sales growth through science-led innovation and expansion into faster-growing markets and channels[128]. - The Prime100 acquisition contributed 1.6% to volume in Hill's Pet Nutrition, despite a decline in private label volume impacting organic sales[175]. - The company is focused on driving organic sales growth and operational efficiencies to achieve consistent compounded earnings per share growth[114]. Market Conditions - The company has faced challenges from heightened competitive activity, including aggressive product claims and increased promotional spending[125]. - The ongoing geopolitical tensions, including the war in Ukraine and conflicts in the Middle East, have created uncertainties impacting the company's operations[127]. - The company has ongoing federal, state, and international income tax audits, with an estimated tax plus interest for the years 2010 through 2018 amounting to approximately $162 million[203]. Cash Flow and Investments - Net cash provided by operations decreased by 3% to $2,745 million in the first nine months of 2025 compared to $2,838 million in the same period of 2024[226]. - Investing activities used $714 million in cash during the first nine months of 2025, an increase from $454 million in the same period of 2024[227]. - Capital expenditures for the first nine months of 2025 were $387 million, expected to be approximately 3.0% of net sales[228]. - Total debt increased to $8,419 million as of September 30, 2025, from $7,949 million as of December 31, 2024[230]. - Cash and cash equivalents increased by $183 million to $1,279 million as of September 30, 2025, compared to $1,096 million at December 31, 2024[235]. Tax and Regulatory Matters - The IRS has issued temporary relief from certain tax regulations, allowing taxpayers to defer the application of these regulations through the end of 2023[200]. - The company believes that the Pillar II minimum tax regime will not have a material impact on its consolidated financial statements going forward[202]. - The company continues to evaluate the impact of proposed IRS regulations related to the 15% minimum tax on book income, which is expected to have no significant effect if finalized in their current form[201]. Internal Controls - The Company is upgrading its enterprise IT system and transitioning to cloud infrastructure, which is not expected to materially impact internal controls over financial reporting[245]. - There were no changes in the Company's internal control over financial reporting during the most recent fiscal quarter that materially affected or are likely to affect it[246].

Financial Performance - Net sales for Q3 2025 reached $961.1 million, a 6% increase from $909.3 million in Q3 2024, with core sales growth of 1% after excluding acquisitions and currency effects [182]. - The effective tax rate decreased to 17.1% in Q3 2025 from 23.8% in Q3 2024, contributing to a net income of $128.5 million, up from $100.0 million in the prior year [200]. - Operating income for the first nine months of 2025 increased by approximately $18.4 million to $394.8 million, with an operating income margin of 14.0% compared to 13.8% in the same period of 2024 [201]. - Net income attributable to AptarGroup, Inc. for the three months ended September 30, 2025, was $127.9 million, up from $100.0 million in the same period of 2024, representing a 28% increase [211]. - Reported net income for the same period was $318,227, with a reported net income margin of 11.3% [252]. - The company reported a net income of $127.8 million for the quarter ended September 30, 2025 [248]. Segment Performance - Net sales for the Aptar Pharma segment increased by 6% in Q3 2025 to $445.4 million compared to $420.6 million in Q3 2024, with core sales growth of 2% [214]. - Adjusted EBITDA for the Aptar Pharma segment in Q3 2025 increased by 9% to $165.8 million, resulting in an Adjusted EBITDA margin of 37.2%, up from 36.0% in Q3 2024 [218]. - Reported net sales for the Aptar Beauty segment increased by 8% to $327.8 million in Q3 2025 compared to $302.9 million in Q3 2024, with core sales remaining flat [224]. - Adjusted EBITDA for the Aptar Beauty segment in Q3 2025 decreased by 1% to $39.7 million, leading to a decline in Adjusted EBITDA margin from 13.3% in Q3 2024 to 12.1% in Q3 2025 [227]. - Net sales for the Aptar Closures segment increased approximately 1% to $188.0 million in Q3 2025 compared to $185.8 million in Q3 2024, with core sales decreasing by about 1% [232]. Expenses and Costs - Selling, general and administrative expenses (SG&A) rose to $148.8 million in Q3 2025, up from $141.6 million in Q3 2024, but as a percentage of net sales, it decreased to 15.5% [190]. - Cost of sales as a percentage of net sales increased to 62.2% in Q3 2025 from 61.4% in Q3 2024, primarily due to lower margin applications in the Pharma segment [187]. - Depreciation and amortization expenses increased to $75.2 million in Q3 2025, up from $67.0 million in Q3 2024, reflecting higher capital investments and recent acquisitions [193]. - Interest expense increased to $13.5 million in Q3 2025, up from $12.3 million in Q3 2024, due to higher rates on current borrowings [203]. - The company recognized $2.2 million in restructuring costs for Q3 2025, down from $3.9 million in Q3 2024, with cumulative restructuring expenses totaling $70.5 million as of September 30, 2025 [197]. Cash Flow and Debt - Free Cash Flow for the nine months ended September 30, 2025, was $206.0 million, down from $254.8 million for the same period in 2024 [268]. - Net Debt increased to $935.8 million as of September 30, 2025, from $800.2 million at December 31, 2024, resulting in a Net Debt to Net Capital ratio of 25.1% [267]. - Total Debt rose to $1.2 billion at September 30, 2025, compared to $1.03 billion at December 31, 2024 [267]. - The company utilized $141.1 million under its Term Loan facility as of September 30, 2025 [273]. - The Consolidated Leverage Ratio was 1.22 to 1.00 as of September 30, 2025, well below the maximum requirement of 3.50 to 1.00 [273]. Tax and Future Projections - The effective tax rate for the fourth quarter of 2025 is expected to range from 19.5% to 21.5% [282]. - The company expects adjusted earnings per share for Q4 2025 to be in the range of $1.20 to $1.28 [282]. Foreign Exchange and Hedging - The company has a significant foreign exchange exposure primarily to the euro, with additional exposure to currencies such as the Chinese yuan and Brazilian real [288]. - A weakening U.S. dollar relative to foreign currencies has a positive translation effect on the company's financial statements, while a strengthening dollar has a negative effect [288]. - The company entered into a seven-year USD/EUR fixed-to-fixed cross currency interest rate swap to hedge interest rate exposure related to $203 million of debt [290]. - The fair value of the net investment hedge from the USD/EUR swap agreement is reported at $33.8 million in liabilities [290]. - The company has recorded $0.1 million in prepaid and other assets and $0.9 million in liabilities related to foreign currency forward exchange contracts [290]. - The company’s foreign currency contracts primarily expire before the end of the fourth quarter of 2025 [289]. General Remarks - The company continues to focus on strategic acquisitions and restructuring initiatives to enhance operational efficiency and market presence [252]. - The company cautions that actual results may differ materially from forward-looking statements due to various risks and uncertainties [286].

IPO and Financing - The company completed its IPO on September 13, 2024, issuing 5,000,000 Units at $10.00 per Unit, generating gross proceeds of $50,000,000, with offering costs of $1,845,513[102] - An over-allotment option was exercised, resulting in an additional $7,500,000 in gross proceeds deposited into the Trust Account[102] - A private placement of 299,000 units was made to the Sponsor at $10.00 per Unit, generating gross proceeds of $2,990,000[103] Financial Performance - As of September 30, 2025, the company reported a net income of $1,563,409, primarily from interest income on marketable securities and bank accounts[107] - The company had cash of $1,108,123 and marketable securities held in the Trust Account amounting to $60,451,218 as of September 30, 2025[111] - The company has no revenue and has incurred losses since inception, relying on working capital from the IPO and loans from the Sponsor[105] Business Combination and Liquidation - The company expects to incur significant costs related to being a public company and pursuing a Business Combination[106] - A deferred underwriting commission of $575,000 is payable to underwriters from the Trust Account upon consummation of a Business Combination[112] - If a Business Combination is not completed by March 31, 2026, the company may commence voluntary liquidation[115] Accounting and Regulatory Matters - The company has no off-balance sheet arrangements or long-term liabilities as of September 30, 2025[116] - FASB issued ASU 2023-09, effective after December 15, 2024, requiring incremental income tax disclosures; management expects no material impact on financial statements[125] - FASB issued ASU 2024-03, effective after December 15, 2026, requiring detailed expense disaggregation in income statements; management anticipates no material impact on financial statements[126] - Management believes that recently issued accounting pronouncements will not materially affect financial statements if adopted[127] - As a smaller reporting company, the entity is not required to disclose market risk information[128]

OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ FUTURE VISION II ACQUISITION CORP. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-422273 N/A (State or Other Jurisdic ...

Financial Position - As of June 30, 2025, total accounts receivable amounted to US$108,999, a decrease of 1% from US$111,066 in 2024, with an allowance for expected credit loss of US$134,958[727] - Total inventories, net as of June 30, 2025, decreased by 36.6% to US$103,914 from US$163,993 in 2024, with a significant reversal of stock obsolescence allowance by US$21,172[728] - The Company reported a total of US$377,291 in other current assets as of June 30, 2025, an increase from US$222,737 in 2024, driven by a rise in other receivables to US$205,910[729] - Property and equipment net book value as of June 30, 2025, was US$138,421, down from US$216,047 in 2024, with depreciation expenses increasing to US$140,766 from US$96,963[732] - Intangible assets net book value as of June 30, 2025, was US$2,360,937, reflecting an addition of US$2,373,237 in development costs[733] - Total reportable assets as of June 30, 2025, were US$4,447,950, a decrease from US$7,950,615 in 2024, representing a decline of 44.4%[768] Liabilities and Equity - Accruals and other payables totaled US$563,530 as of June 30, 2025, a decrease from US$1,078,094 in 2024, primarily due to a reduction in staff salaries accruals[742] - As of June 30, 2025, the Company had lease liabilities of US$168,948, down from US$376,010 in 2024, reflecting a reduction in operating lease commitments[740] - The Company recognized operating lease costs of US$279,192 for the year ended June 30, 2025, compared to US$195,674 in 2024, with a weighted average remaining lease term of 0.55 years[741] - The Company issued a total of 24,900 Class A Ordinary Shares at US$94 per share, raising US$1,724,073 from August 2023 to January 2024[746] - The Company entered into a standby equity subscription agreement on February 14, 2025, allowing for the issuance of up to US$10 million in Class A Ordinary Shares over 36 months[755] - As of June 30, 2025, the Company had issued a total of 156,128 Class A Ordinary Shares, raising gross proceeds of US$984,053 through the Subscription Agreement[760] Revenue and Profitability - Total revenue for the year ended June 30, 2025, was US$7,646,739, a decrease of 45.1% from US$13,968,535 in 2024[766] - Telemedicine and other services generated revenue of US$6,800,287 in 2025, down from US$12,857,688 in 2024, representing a decline of 47.2%[768] - The net loss for the year ended June 30, 2025, was US$3,383,806, compared to a net loss of US$15,602,792 in 2024, indicating a reduction in losses by 78.3%[793] - Gross profit for the telemedicine segment was US$1,169,734 in 2025, down from US$2,369,921 in 2024, reflecting a decrease of 50.7%[768] - Employee welfare benefits expenses totaled US$1,569,769 in 2025, significantly lower than US$4,045,692 in 2024, marking a decrease of 61.1%[769] - The Company recognized share-based compensation of US$414,051 in 2025, a substantial decrease from US$9,119,764 in 2024[780] Shareholder Actions - On February 19, 2024, the Company completed a share subdivision, increasing the number of Class A Ordinary Shares from 78,687 to 491,794 and Class B Ordinary Shares from 48,313 to 301,956[748] - The initial public offering on April 12, 2024, resulted in the issuance of 64,688 Class A Ordinary Shares at a price of US$160.00 each[750] - On April 19, 2024, the Underwriter exercised warrants, resulting in the issuance of 3,855 Class A Ordinary Shares[751] - A share consolidation was approved on February 3, 2025, combining every eight existing Class A and Class B Ordinary Shares into one[752] - Following the share consolidation on February 28, 2025, the number of outstanding Class A Ordinary Shares was reduced from 22,816,212 to approximately 2,852,027[753] - The Company began trading on the Nasdaq under the symbol "MNDR" on March 10, 2025, after the share consolidation[754] Risk Management - The company has designed credit policies to minimize exposure to credit risk, with accounts receivable being short-term in nature[590] - The company’s operations are exposed to foreign exchange rate fluctuations, particularly between SGD and the U.S. dollar[595] - The company has not experienced any losses in its bank accounts and believes it is not exposed to significant risks related to cash held in banks[590] - As of June 30, 2025, no single customer represented more than 10% of the company's total accounts receivable, indicating a diversified customer base[591] Other Information - The estimated future amortization expenses for definite-lived intangible assets are projected to total US$2,360,937 over the next several years, with US$130,373 expected in 2026[735] - The effective tax rate for the Company remained at 0.0% for the years ended June 30, 2025, 2024, and 2023, due to continuous net operating losses[778] - The Company granted a total of 66,404 restricted shares in June 2025, with a fair value of US$6.10 per share[789] - The company has entered into lease agreements for office premises in Singapore and Vietnam, with a total monthly lease fee of approximately $21,000[794] - The company has a sales agreement allowing it to sell up to $300,000,000 of Class A ordinary shares through an agent, with a 3.0% compensation on gross proceeds[795] - The company issued 22,485 Class A ordinary shares for $200,000 and agreed to issue an additional 100,000 shares at $9.00 per share for $900,000 as part of an acquisition strategy[796] - A 1-for-5 reverse stock split was approved, resulting in the authorized share capital remaining at $50,000, divided into 312,500,000 ordinary shares[798] - The company has not disclosed any material subsequent events that require further disclosure in its consolidated financial statements[797]

Exhibit 99.1 RBC Bearings Incorporated Announces Fiscal Second Quarter 2026 Results Oxford, CT – October 31, 2025 – RBC Bearings Incorporated (NYSE: RBC), a leading international manufacturer of highly engineered precision bearings, components and essential systems for the industrial, defense and aerospace industries, today reported results for the second quarter fiscal 2026. (1) Results exclude items in reconciliation below. ● Second quarter net sales of $455.3 million increased 14.4% over last year, Aeros ...

Exhibit 10.1 JAKKS PACIFIC REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS Board approves Quarterly Cash Dividend SANTA MONICA, California, October 30, 2025 – JAKKS Pacific, Inc. (NASDAQ: JAKK) today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 First Nine Months 2025 ● Net sales were $211.2 million, a year-over-year decrease of $110.4 million or 34%, driven largely by a reduction in direct- import sales due to a combination of customers anticipating lower consum ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to 001-34809 Commission File Number GLOBAL INDEMNITY GROUP, LLC (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...